Anavex Life Sciences (AVXL) 0.1620 $AVXL
Anavex Confirms Positive Preclinical Epilepsy Data for ANAVEX 2-73 - Validation as Potential Platform Drug for Multiple Neurodegenerative Diseases
M2 - Mon Feb 09, 9:51AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(AVXL) today confirmed positive preclinical data for its lead drug candidate ANAVEX 2-73 for the potential treatment of epilepsy, validating it also as a prospective platform drug for the treatment of other neurodegenerative diseases beyond Alzheimer's. The data demonstrates significant improvement in the reduction of seizures relative to three generations of epilepsy drugs currently on the market, as well as significant synergy with each of these drugs. ANAVEX 2-73 has successfully completed a Phase 1 human clinical trial, in which it was shown to be safe, and is currently in a Phase 2a clinical trial for Alzheimer's disease.
Anavex to Present at 17th Annual BIO CEO & Investor Conference on February 10th
M2 - Thu Feb 05, 11:44AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company" (AVXL) today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present at the 17th Annual BIO CEO & Investor Conference on Tuesday, February 10, 2015 at 11:30 a.m. ET at the Waldorf-Astoria Hotel, Louis XVI room, in New York, NY. Investors may view Dr. Missling's presentation via live webcast on the BIO website or access an archived version via Anavex.com.
Anavex Doses First Alzheimer's Patient in Phase 2a Trial of ANAVEX 2-73 and ANAVEX PLUS
M2 - Tue Jan 13, 6:45AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company" (AVXL) today announced dosing of the first patient in the Phase 2a clinical trial of ANAVEX 2-73 and ANAVEX PLUS, which are being developed as an oral therapy and oral drug combination for the potential treatment of Alzheimer's disease. In preclinical studies, ANAVEX 2-73 was shown to prevent, halt and/or reverse Alzheimer's disease by targeting sigma-1 and muscarinic receptors. The drug therapeutic showed no serious adverse events in a successfully completed Phase 1 human study.
Anavex Announces Panel Discussion and Presention at OneMedForum Conference
M2 - Fri Jan 09, 5:22AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company" (AVXL), a clinical stage biopharmaceutical company currently in a Phase2a clinical trial for Alzheimer's disease, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will participate in a panel discussion entitled "Neurology and Brain Health" and will present at the 8th Annual OneMedForum conference in San Francisco. OneMedForum is recognized as a leading annual event showcasing promising, innovative growth companies in healthcare and life sciences.
Anavex Encouraged by Scientific Data Confirming Sigma-1 Receptor's Beneficial Direct Interaction With Cannabinoid Receptor
M2 - Wed Jan 07, 7:07AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company" (AVXL) welcomes new data published in the current issue of the International Journal of Neuropsychopharmacology (IJNP) revealing that the sigma-1 receptor, the Company's drug target, interacts positively and directly with the cannabinoid receptor. The current scientific findings indicate that sigma-1 receptor modulation may protect against psychosis possibly connected to cannabis (marijuana) abuse, especially among the young, whose nervous systems are still maturing, or individuals with a genetic predisposition, which could potentially lead to schizophrenia.
Anavex Announces Fiscal 2014 Fourth Quarter and Year-End Financial Results
GlobeNewswire - Tue Dec 30, 6:11AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQX:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, today reported fourth quarter and year-end results for fiscal year 2014.
Anavex to Present at Biotech Showcase 2015 in San Francisco
GlobeNewswire - Thu Dec 18, 6:17AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQX:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, will present at Biotech Showcase 2015 on Monday January 12, 2015 at 2:00pm PST. The investor and partnering conference will take place at the Parc 55 Wyndham San Francisco - Union Square.
Anavex Begins Enrollment of Alzheimer's Patients in Phase 2a Clinical Trial of ANAVEX 2-73 and ANAVEX PLUS
GlobeNewswire - Tue Dec 16, 6:23AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQX:AVXL) today announced enrollment of the first patient in a multicenter Phase 2a clinical trial for ANAVEX 2-73, which is being evaluated for the treatment of Alzheimer's disease. The randomized trial is designed to assess the safety and exploratory efficacy of ANAVEX 2-73 alone as well as in combination with donepezil (ANAVEX PLUS) in patients with mild to moderate Alzheimer's disease. ANAVEX 2-73 targets sigma-1 and muscarinic receptors, which have been shown in preclinical studies to reduce stress levels in the brain and to reverse the pathological hallmarks observed in Alzheimer's disease. ANAVEX 2-73 showed no serious adverse events in a previously performed Phase 1 study.
Anavex Life Sciences to trade on OTCQX
M2 - Mon Dec 15, 5:50AM CST
OTC Markets Group (OtherOTC:OTCM) disclosed on Friday that Anavex Life Sciences has qualified to trade on OTCQX today under the symbol "AVXL."
Anavex Upgrades to OTCQX Marketplace
GlobeNewswire - Fri Dec 12, 6:11AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQX:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, today announces that the Company is now trading on the OTCQX marketplace under the Company's existing stock ticker AVXL. OTCQX is the best marketplace for established, global and growth companies operated by OTC Markets Group Inc.
OTC Markets Group Welcomes Anavex Life Sciences to OTCQX®
PR Newswire - Fri Dec 12, 6:00AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced that Anavex Life Sciences Corp. ("Anavex" (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS), and various types of cancer, has qualified to trade on OTCQX®, the best marketplace for established, global and growth companies.
Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/9rd5zp/amyotrophic) has announced the addition of the "Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Amyotrophic Lateral Sclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Amyotrophic Lateral Sclerosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - AB Science - Aestus Therapeutics - AlzProtect - Amorfix Life Sciences - Anavex Life Sciences - Angion Biomedica - Apodemus - BBB Therapeutics - BioCrea - Biogen Idec - Bionure Farma - BrainStorm Cell Therapeutics - CalAsia Pharmaceuticals - Calico - Cellceutix - Cellular Biomedicine Group - Chronos Therapeutics Limited - Cytokinetics - D-Pharm - Daval International Ltd. - Eisai Co., Ltd. - Evotec AG - ExSAR Corporation - Genervon Biopharmaceuticals, LLC - GlaxoSmithKline plc - Glialogix, Inc. - Grifols, S.A. - Herantis Pharma plc. - ImStar Therapeutics Inc. - Jeil Pharmaceutical Co., Ltd. - Kadimastem Ltd. - KineMed, Inc. - Kringle Pharma, Inc. - Kyorin Pharmaceutical Co., Ltd. - Lead Discovery Center GmbH - Maas Biolab - Mallinckrodt plc - miRagen Therapeutics, Inc. - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neuraltus Pharmaceuticals, Inc. - Neurimmune Holding AG - Neurodyn Inc. - Neurotec Pharma SL - Neurotune AG - Newron Pharmaceuticals S.p.A. - Nexgenix Pharmaceuticals, LLC - Orphazyme ApS - Paladin Labs Inc. - Pharnext SAS - Q Therapeutics, Inc. - Regenesance BV - reMYND - RhinoCyte, Inc. - RXi Pharmaceuticals Corporation - Saneron CCEL Therapeutics, Inc. - SK Biopharmaceuticals Co., Ltd. - Spherium biomed S.L. - Varinel, Inc. - ViroMed Co., Ltd. For more information visit http://www.researchandmarkets.com/research/9r...myotrophic
BIIB: 391.66 (-0.45), KNMD: (), GSK: 47.94 (+1.99), BCLI: 3.86 (-0.02), CBMG: 24.32 (-1.17), CUR: 3.41 (+0.13)
Anavex Announces Positive Phase 1 Data for ANAVEX 2-73, Lead Candidate for the Treatment of Alzheimer's
GlobeNewswire - Mon Nov 17, 6:17AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL) announced full data results from the Phase 1 clinical trial of ANAVEX 2-73, the Company's lead investigational oral treatment for Alzheimer's, which has shown potential in preclinical studies to prevent, halt and/or reverse the course of the disease. Observed adverse events included moderate and reversible headache and dizziness, which is common in drugs that target central nervous system (CNS) conditions, including Alzheimer's. No serious side effects were reported in this randomized, double-blind, placebo-controlled study, there was no study discontinuation due to adverse events, ANAVEX 2-73 was found to be safe and well tolerated, and the results indicate a favorable pharmacokinetics profile. Findings from the Phase 1 clinical trial were presented at CNS Summit 2014 in Boca Raton, Florida. A Phase 2a clinical trial of ANAVEX 2-73 and ANAVEX PLUS, the combination of ANAVEX 2-73 and donepezil (Aricept(R)), is now underway.
Anavex Confirms Positive Preclinical Epilepsy Data for ANAVEX 2-73 - Validation as Potential Platform Drug for Multiple Neurodegenerative Diseases
M2 - Mon Feb 09, 9:51AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(AVXL) today confirmed positive preclinical data for its lead drug candidate ANAVEX 2-73 for the potential treatment of epilepsy, validating it also as a prospective platform drug for the treatment of other neurodegenerative diseases beyond Alzheimer's. The data demonstrates significant improvement in the reduction of seizures relative to three generations of epilepsy drugs currently on the market, as well as significant synergy with each of these drugs. ANAVEX 2-73 has successfully completed a Phase 1 human clinical trial, in which it was shown to be safe, and is currently in a Phase 2a clinical trial for Alzheimer's disease. Anavex to Present at 17th Annual BIO CEO & Investor Conference on February 10th
M2 - Thu Feb 05, 11:44AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(AVXL) today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present at the 17th Annual BIO CEO & Investor Conference on Tuesday, February 10, 2015 at 11:30 a.m. ET at the Waldorf-Astoria Hotel, Louis XVI room, in New York, NY. Investors may view Dr. Missling's presentation via live webcast on the BIO website or access an archived version via Anavex.com. Anavex Doses First Alzheimer's Patient in Phase 2a Trial of ANAVEX 2-73 and ANAVEX PLUS
M2 - Tue Jan 13, 6:45AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(AVXL) today announced dosing of the first patient in the Phase 2a clinical trial of ANAVEX 2-73 and ANAVEX PLUS, which are being developed as an oral therapy and oral drug combination for the potential treatment of Alzheimer's disease. In preclinical studies, ANAVEX 2-73 was shown to prevent, halt and/or reverse Alzheimer's disease by targeting sigma-1 and muscarinic receptors. The drug therapeutic showed no serious adverse events in a successfully completed Phase 1 human study. Anavex Announces Panel Discussion and Presention at OneMedForum Conference
M2 - Fri Jan 09, 5:22AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(AVXL), a clinical stage biopharmaceutical company currently in a Phase2a clinical trial for Alzheimer's disease, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will participate in a panel discussion entitled "Neurology and Brain Health" and will present at the 8th Annual OneMedForum conference in San Francisco. OneMedForum is recognized as a leading annual event showcasing promising, innovative growth companies in healthcare and life sciences. Anavex Encouraged by Scientific Data Confirming Sigma-1 Receptor's Beneficial Direct Interaction With Cannabinoid Receptor
M2 - Wed Jan 07, 7:07AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(AVXL) welcomes new data published in the current issue of the International Journal of Neuropsychopharmacology (IJNP) revealing that the sigma-1 receptor, the Company's drug target, interacts positively and directly with the cannabinoid receptor. The current scientific findings indicate that sigma-1 receptor modulation may protect against psychosis possibly connected to cannabis (marijuana) abuse, especially among the young, whose nervous systems are still maturing, or individuals with a genetic predisposition, which could potentially lead to schizophrenia. Anavex Announces Fiscal 2014 Fourth Quarter and Year-End Financial Results
GlobeNewswire - Tue Dec 30, 6:11AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQX:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, today reported fourth quarter and year-end results for fiscal year 2014. Anavex to Present at Biotech Showcase 2015 in San Francisco
GlobeNewswire - Thu Dec 18, 6:17AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQX:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, will present at Biotech Showcase 2015 on Monday January 12, 2015 at 2:00pm PST. The investor and partnering conference will take place at the Parc 55 Wyndham San Francisco - Union Square. Anavex Begins Enrollment of Alzheimer's Patients in Phase 2a Clinical Trial of ANAVEX 2-73 and ANAVEX PLUS
GlobeNewswire - Tue Dec 16, 6:23AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQX:AVXL) today announced enrollment of the first patient in a multicenter Phase 2a clinical trial for ANAVEX 2-73, which is being evaluated for the treatment of Alzheimer's disease. The randomized trial is designed to assess the safety and exploratory efficacy of ANAVEX 2-73 alone as well as in combination with donepezil (ANAVEX PLUS) in patients with mild to moderate Alzheimer's disease. ANAVEX 2-73 targets sigma-1 and muscarinic receptors, which have been shown in preclinical studies to reduce stress levels in the brain and to reverse the pathological hallmarks observed in Alzheimer's disease. ANAVEX 2-73 showed no serious adverse events in a previously performed Phase 1 study. Anavex Life Sciences to trade on OTCQX
M2 - Mon Dec 15, 5:50AM CST
OTC Markets Group (OtherOTC:OTCM) disclosed on Friday that Anavex Life Sciences has qualified to trade on OTCQX today under the symbol "AVXL."
Anavex Upgrades to OTCQX Marketplace
GlobeNewswire - Fri Dec 12, 6:11AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQX:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, today announces that the Company is now trading on the OTCQX marketplace under the Company's existing stock ticker AVXL. OTCQX is the best marketplace for established, global and growth companies operated by OTC Markets Group Inc. OTC Markets Group Welcomes Anavex Life Sciences to OTCQX®
PR Newswire - Fri Dec 12, 6:00AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced that Anavex Life Sciences Corp. ("Anavex"
(OTCQX: AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS), and various types of cancer, has qualified to trade on OTCQX®, the best marketplace for established, global and growth companies. Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/9rd5zp/amyotrophic) has announced the addition of the "Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Amyotrophic Lateral Sclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Amyotrophic Lateral Sclerosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - AB Science - Aestus Therapeutics - AlzProtect - Amorfix Life Sciences - Anavex Life Sciences - Angion Biomedica - Apodemus - BBB Therapeutics - BioCrea - Biogen Idec - Bionure Farma - BrainStorm Cell Therapeutics - CalAsia Pharmaceuticals - Calico - Cellceutix - Cellular Biomedicine Group - Chronos Therapeutics Limited - Cytokinetics - D-Pharm - Daval International Ltd. - Eisai Co., Ltd. - Evotec AG - ExSAR Corporation - Genervon Biopharmaceuticals, LLC - GlaxoSmithKline plc - Glialogix, Inc. - Grifols, S.A. - Herantis Pharma plc. - ImStar Therapeutics Inc. - Jeil Pharmaceutical Co., Ltd. - Kadimastem Ltd. - KineMed, Inc. - Kringle Pharma, Inc. - Kyorin Pharmaceutical Co., Ltd. - Lead Discovery Center GmbH - Maas Biolab - Mallinckrodt plc - miRagen Therapeutics, Inc. - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neuraltus Pharmaceuticals, Inc. - Neurimmune Holding AG - Neurodyn Inc. - Neurotec Pharma SL - Neurotune AG - Newron Pharmaceuticals S.p.A. - Nexgenix Pharmaceuticals, LLC - Orphazyme ApS - Paladin Labs Inc. - Pharnext SAS - Q Therapeutics, Inc. - Regenesance BV - reMYND - RhinoCyte, Inc. - RXi Pharmaceuticals Corporation - Saneron CCEL Therapeutics, Inc. - SK Biopharmaceuticals Co., Ltd. - Spherium biomed S.L. - Varinel, Inc. - ViroMed Co., Ltd. For more information visit http://www.researchandmarkets.com/research/9r...myotrophic
BIIB: 391.66 (-0.45), KNMD: (), GSK: 47.94 (+1.99), BCLI: 3.86 (-0.02), CBMG: 24.32 (-1.17), CUR: 3.41 (+0.13)
Anavex Announces Positive Phase 1 Data for ANAVEX 2-73, Lead Candidate for the Treatment of Alzheimer's
GlobeNewswire - Mon Nov 17, 6:17AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQB:AVXL) announced full data results from the Phase 1 clinical trial of ANAVEX 2-73, the Company's lead investigational oral treatment for Alzheimer's, which has shown potential in preclinical studies to prevent, halt and/or reverse the course of the disease. Observed adverse events included moderate and reversible headache and dizziness, which is common in drugs that target central nervous system (CNS) conditions, including Alzheimer's. No serious side effects were reported in this randomized, double-blind, placebo-controlled study, there was no study discontinuation due to adverse events, ANAVEX 2-73 was found to be safe and well tolerated, and the results indicate a favorable pharmacokinetics profile. Findings from the Phase 1 clinical trial were presented at CNS Summit 2014 in Boca Raton, Florida. A Phase 2a clinical trial of ANAVEX 2-73 and ANAVEX PLUS, the combination of ANAVEX 2-73 and donepezil (Aricept(R)), is now underway. 
